首页> 外文学位 >Clinical and pre-clinical pharmacokinetics of green tea polyphenols.
【24h】

Clinical and pre-clinical pharmacokinetics of green tea polyphenols.

机译:绿茶多酚的临床和临床前药代动力学。

获取原文
获取原文并翻译 | 示例

摘要

Tea consumption has been suggested to have beneficial effects for human health, especially in cancer prevention. At present, epidemiological evidence of the protective effect of tea consumption against the development of human cancer is not conclusive. Interpretation of epidemiological data and extrapolation of rodent data to humans are generally hampered by inadequate information on the bioavailability and pharmacokinetics of tea constituents. We have performed studies to determine the pharmacokinetics of green tea in humans after single and multiple oral dose administration of tea polyphenols and the contribution of hepatic first-pass elimination to the low oral bioavailability of green tea catechins in animals.;EGCG was present in the systemic blood in the unchanged form in humans after oral administration of two green tea polyphenol products, EGCG and Polyphenon E (a mixture of major green tea polyphenols). Oral administration of EGCG and Polyphenon E resulted in similar systemic exposure of EGCG. EGC and EC were present in glucuronic acid/sulfate conjugates in blood and urine samples after the Polyphenon E administration. Large inter-subject variations in the systemic levels of green tea catechins were observed following oral administration of green tea polyphenols.;We found that it is safe for healthy human subjects to take green tea polyphenols for four weeks in amounts equivalent to those contained in 8 to 16 cups of green tea once a day or in divided doses twice a day. Systemic availability of EGCG increased more than 60% after chronic green tea polyphenol administration at high doses once a day. Oral administration of green tea polyphenols at the selected doses and dosing schedules did not elicit overall changes in the selected pharmacodynamic measurements.;Oral bioavailability of green tea catechins was demonstrated to be low in animals and possibly in humans. Based on our pre-clinical study, we found that first-pass hepatic elimination of green tea catechins didn't play a significant role in the presystemic elimination of orally administered catechins. Factors within the gastrointestinal tract such as limited membrane permeability, transporter mediated intestinal secretion, or gut wall metabolism may contribute more significantly to the low oral bioavailability of green tea catechins.
机译:已建议食用茶对人体健康,特别是在预防癌症方面具有有益的作用。目前,尚无关于饮用茶对人类癌症发展具有保护作用的流行病学证据。关于茶叶成分的生物利用度和药代动力学的信息不足,通常会​​阻碍流行病学数据的解释和啮齿动物数据对人类的外推。我们进行了研究以确定单次或多次口服茶多酚后绿茶在人体中的药代动力学以及肝首过消除对动物中绿茶儿茶素低口服生物利用度的影响。口服两种绿茶多酚产品EGCG和Polyphenon E(主要绿茶多酚的混合物)后,人体的全身血液处于不变的形式。口服EGCG和Polyphenon E导致类似的EGCG全身暴露。施用Polyphenon E后,血液和尿液样品中的葡萄糖醛酸/硫酸盐结合物中存在EGC和EC。口服绿茶多酚后观察到绿茶儿茶素的全身水平存在较大的受试者间差异;我们发现健康的人类受试者服用绿茶多酚4周的量相当于8中所含的含量是安全的每天一次至16杯绿茶或每天两次分次服用。在每天一次以高剂量长期服用绿茶多酚后,EGCG的全身利用率增加了60%以上。以选定的剂量和给药时间表口服绿茶多酚并没有引起所选药效学测量的总体变化。事实证明,动物和人中绿茶儿茶素的口服生物利用度较低。根据我们的临床前研究,我们发现,肝脏通过的绿茶儿茶素的首过清除在口服给予儿茶素的系统性清除中没有发挥重要作用。胃肠道内的因素,例如有限的膜通透性,转运蛋白介导的肠道分泌或肠壁代谢,可能对绿茶儿茶素的低口服生物利用度有更大的影响。

著录项

  • 作者

    Cai, Yan.;

  • 作者单位

    The University of Arizona.;

  • 授予单位 The University of Arizona.;
  • 学科 Health Sciences Pharmacy.
  • 学位 Ph.D.
  • 年度 2002
  • 页码 130 p.
  • 总页数 130
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号